BSX · News · 20261102N
Acquisition / Partnership / Divestiture
BOSTON SCIENTIFIC CORP · 2026-11-02 · Importance 58 · Surprise 42 · In source text
Blackstone Life Sciences announced a $455 million collaboration with Boston Scientific to co-fund development of the VITALYST Temporary Percutaneous Transvalvular Circulatory Support System program. VITALYST is a temporary heart pump under development for patients with acute myocardial infarction cardiogenic shock. The announcement described this as the first product-development program co-funded by Boston Scientific and Blackstone Life Sciences.
Key facts
- Blackstone Life Sciences announced a $455 million collaboration with Boston Scientific to co-fund development of the VITALYST Temporary Percutaneous Transvalvular Circulatory Support System program. source
- Boston Scientific anticipated that its Penumbra acquisition would close in early 2027. source
- Boston Scientific completed acquisitions of Nalu Medical and Scivita Medical. source
- The VITALYST collaboration was the first time Boston Scientific and Blackstone Life Sciences co-funded development of a Boston Scientific product. source
- Boston Scientific was progressing on its acquisition of Penumbra. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| cash | positive | committed | — | Blackstone Life Sciences announced a $455 million collaboration with Boston Scientific to co-fund development of the VITALYST Temporary… |